Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Trial of L-NMMA and Pembrolizumab in Advanced Cancers
NCT03236935Phase 1Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Aug 2018
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of NG-monomethyl-L-arginine in melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 13 more (3 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Maximum Tolerated Dose at 18 weeks. Started Aug 2018; status: completed.
02
Drugs
NG-monomethyl-L-arginine
03
Conditions
melanomanon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)classical Hodgkin lymphoma (cHL)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03236935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236935.